Ali Erginay · enciclopedia

Publicaciones › Edema macular diabético y sus tratamientos

Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema: Phase 2 Trial Comparing 4 mg vs 2 mg

Triamcinolona acetonida intravítrea para edema macular diabético difuso: Ensayo de fase 2 comparando 4 mg vs 2 mg

Año2006
FuenteAmerican journal of ophthalmology
Tipoarticle · Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial
Autores (8)François Audren, Amélie Lecleire-Collet, Ali Erginay, Belkacem Haouchine, Rym Benosman, Jean-François Bergmann, Alain Gaudric, Pascale Massin
Posición de Erginay3 de 8
Citas97 (OpenAlex)
EnlacesDOI 10.1016/j.ajo.2006.06.011 · PubMed 16978576 · OpenAlex
LíneasEdema macular diabético y sus tratamientos Enfermedades vasculares, genéticas e inflamatorias de la retina Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo

En pocas palabras

Se estudió la efectividad y seguridad de dos dosis de triamcinolona acetonida para tratar el edema macular diabético. Los pacientes recibieron una inyección intravítrea de 4 mg o 2 mg y se midió el grosor de la mácula y la agudeza visual. No se encontraron diferencias significativas entre las dos dosis en cuanto a grosor de la mácula, agudeza visual o presión intraocular.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

To prospectively compare the efficacy and safety of 4 vs 2 mg intravitreal triamcinolone acetonide (TA) injection for diabetic macular edema. Interventional case series. Thirty-two patients with diabetic macular edema unresponsive to laser photocoagulation. Patients were randomly assigned to receive 4 or 2 mg intravitreal TA in one eye (16 patients in each group). The main outcome was central macular thickness (CMT) measured by optical coherence tomography (OCT) at four, 12, and 24 weeks. Secondary outcomes were gain in Early Treatment Diabetic Retinopathy Study (ETDRS) scores, intraocular pressure (IOP), cataract progression, and duration of effect. Before injection, mean (+/- SD) CMT was 564.5 +/- 119 microm and 522.9 +/- 148.5 microm in the 4- and 2-mg groups, respectively. At four, 12, and 24 weeks after injection, it was 275.0 +/- 79.8, 271.4 +/- 128.7, and 448.7 +/- 146.4 microm, respectively, in the 4-mg group, and 267.3 +/- 82.4, 289.8 +/- 111.4, and 394.7 +/- 178.9 microm, respectively, in the 2-mg group. At no time was the difference in CMT between both groups statistically significant (P> 0.3). The between-group differences in the gain in the ETDRS score and in IOP were not statistically significant either. Diabetic macular edema recurred after a median period of 20 weeks vs 16 weeks in the 4- and 2-mg groups, respectively (P = 0.11). In the short term, intravitreal injection of 4 or 2 mg TA does not have different effects on CMT, visual acuity, or IOP.

Términos MeSH

Adult Aged Aged, 80 and over Cataract Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetic Retinopathy Glucocorticoids Humans Injections Intraocular Pressure Macula Lutea Macular Edema Middle Aged Prospective Studies Recurrence Tomography, Optical Coherence Triamcinolone Acetonide Vitreous Body